טוען...
Reduced Incidence of Invasive Breast Cancer With Raloxifene Among Women at Increased Coronary Risk
BACKGROUND: In the Raloxifene Use for The Heart trial, 10 101 postmenopausal women with coronary heart disease (CHD) or multiple CHD risk factors were randomly assigned to 60 mg/d raloxifene or to placebo and followed for a median of 5.6 years. Raloxifene, a selective estrogen receptor modulator, wa...
שמור ב:
| Main Authors: | , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2008
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3559134/ https://ncbi.nlm.nih.gov/pubmed/18544744 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djn153 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|